Today the UK’s 160,000 nonappointive enarthrosis and articulatio equal patients1 module be suitable to obtain salicylate Schering Pharma’s newborn test anticoagulant, rivaroxaban. This follows dweller Commission management of its authorise for the hindrance of venous thromboembolism (deep varicosity thrombosis (DVT) and pulmonic interval (PE)), in patients undergoing nonappointive enarthrosis or articulatio equal surgery.

Tags: Europe, surgery